We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Btg Plc | LSE:BTG | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 840.00 | 839.00 | 840.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
07/6/2018 09:08 | Davis resigning is the rumour | bargainbob | |
07/6/2018 08:27 | No movement on LSE. Have we been hacked? | cockneytrader | |
07/6/2018 08:02 | Interesting article on BBC News website this morning about a Texas man who nearly died after being bitten by severed snake head. He had to have 26 doses of CroFab!! | spyder | |
07/6/2018 07:59 | Unusual CroFab story | cockneytrader | |
07/6/2018 07:29 | Some questions that may be asked: 1) as the process is irreversible, how does one ensure no accidental placement of the coil. 2) to ensure optimal improvement, what computer models, if any, have been developed to aid treatment regimen. This will be no walk in the park. I hope they are seriously prepared. | cockneytrader | |
06/6/2018 18:08 | A date for your diary - 15th June 2018. This is the day after the FDA Ad Comm meeting on the lung coils. For holders, let's hope it good news. For the record, I have no clue what to expect. | cockneytrader | |
06/6/2018 13:06 | Get 5 free plusonecoins while you wait . | bargainbob | |
06/6/2018 11:02 | Bill, I believe the meeting is 14th June 2018 hxxps://www.fda.gov/ | cockneytrader | |
06/6/2018 10:22 | Bill, if they get positive feedback from FDA ref lung coils, then these will pull back up to £6. If not, it's down to £5. I honestly have no opinion as to what the FDA outcome will be. | cockneytrader | |
06/6/2018 10:11 | After the last results does anyone now have any thoughts as to whether we will have a new trading range in the £5s/£4s or are we likely to see a return to £6 in due course? | billbailey1 | |
06/6/2018 10:04 | Of course, I don't want folk to lose money. And I believe in btg in the longer term. I just want people to be aware of what's going on. | cockneytrader | |
06/6/2018 10:01 | Why? There are potentially more write downs around the corner! | cockneytrader | |
06/6/2018 09:59 | Neither am I, I don't hold any, they went back on my watchlist today. Your £3 - £4 is a pipe dream though. | eastbourne1982 | |
06/6/2018 09:57 | I'm not losing money! | cockneytrader | |
06/6/2018 09:54 | I think you are deluding yourself if you are using IFRS basic EPS. Adjusted basic EPS was 32.9p. Free cash flow was 109 million, well up on last year. | eastbourne1982 | |
06/6/2018 09:53 | Try investors chronicle, x155 according to them. | cockneytrader | |
06/6/2018 09:49 | EPS of 4 pence x 150 = 6 pounds | cockneytrader | |
06/6/2018 09:43 | btg will be taking a decision on Varithena at the end of 2018. that should have many of you thinking about the possibility of a write down/off. then there's Anavip which becomes available in Oct 18. | cockneytrader | |
06/6/2018 09:17 | Agreed, £3-4 would be a great buying opportunity for the future. In the meantime, expect poor sales of Varithena and CroFab competition. £6 was 150x earnings, and folk thought this was good value? | cockneytrader | |
06/6/2018 09:14 | Don't panic. Somewhere near here is a great buying opportunity. Your choice. | kpo115 | |
06/6/2018 08:26 | Might be a long wait.I'm not optimistic about the fda view on PneumRx, could need much more data on costs and risks before they get clearance for the US.Try as I might, I can't find any market feedback from clinics about Varithena.I'm still very heavily invested in BTG, well ahead on a seven year basis, but the lack of growth in share price since 2015 is beginning to scare!Only the interventional oncology and device sections are powering ahead.The recent acquisitions to support these gives some hope.Dum spiro......... | fhmktg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions